Moleculin Biotech (MBRX) Cash from Investing Activities (2016 - 2024)
Moleculin Biotech (MBRX) posted quarterly Cash from Investing Activities of -$13000.0 for Q2 2024, up 13.33% year-over-year from -$11470.6 in Q3 2023, and up 83.95% quarter-over-quarter from -$81000.0 in Q4 2023.
Moleculin Biotech (MBRX) Cash from Investing Activities (2016 - 2024) Analysis & Trends
Moleculin Biotech's Cash from Investing Activities history runs 9 years deep, the most recent figure standing at -$13000.0 for Q2 2024.
- In Q2 2024, Cash from Investing Activities rose 13.33% year-over-year to -$13000.0; the TTM figure through Mar 2025 stood at -$13000.0 (up 89.52% YoY), while the FY2024 annual figure was -$13000.0, up 89.52% from the prior year.
- Cash from Investing Activities for Q2 2024 stood at -$13000.0, up from -$81000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was -$2000.0 in Q1 2020, with the low at -$340000.0 in Q3 2020.
- The 5-year median for Cash from Investing Activities is -$18000.0 (2020), against an average of -$54272.7.
- Peak annual rise in Cash from Investing Activities reached 86.67% in 2020, while the deepest fall reached 4150.0% in 2020.
- Moleculin Biotech's Cash from Investing Activities stood at -$14000.0 in 2020, then tumbled by 35.71% to -$19000.0 in 2021, then sank by 221.05% to -$61000.0 in 2022, then sank by 32.79% to -$81000.0 in 2023, then surged by 83.95% to -$13000.0 in 2024.
- Business Quant data shows MBRX's Cash from Investing Activities at -$13000.0 in Q2 2024, -$81000.0 in Q4 2023, and -$28000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Moleculin Biotech | 3.37 Mn | 3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -13,000.00 |
| Jun 30, 2024 | -13,000.00 |
| Dec 31, 2023 | -81,000.00 |
| Dec 31, 2023 | -81,000.00 |
| Sep 30, 2023 | -28,000.00 |
| Sep 30, 2023 | -28,000.00 |
| Jun 30, 2023 | -15,000.00 |
| Jun 30, 2023 | -15,000.00 |
| Jun 30, 2022 | -61,000.00 |
| Jun 30, 2022 | -61,000.00 |
| Mar 31, 2022 | -6,000.00 |
| Mar 31, 2022 | -6,000.00 |
| Dec 31, 2021 | -19,000.00 |
| Dec 31, 2021 | -19,000.00 |
| Dec 31, 2020 | -14,000.00 |
| Dec 31, 2020 | -14,000.00 |
| Sep 30, 2020 | -340,000.00 |
| Sep 30, 2020 | -340,000.00 |
| Jun 30, 2020 | -18,000.00 |
| Jun 30, 2020 | -18,000.00 |